A one-hour infusion of infliximab during maintenance therapy is safe and well tolerated: A prospective cohort study

Alimentary Pharmacology and Therapeutics

Volumn 34, Issue 2, 2011, Pages 181-187

  Lee, T W ^a   Singh, R ^a   Fedorak, R N ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; DIPHENHYDRAMINE; HYDROCORTISONE; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE;

ABDOMINAL DISCOMFORT; ANKYLOSING SPONDYLITIS; ARTICLE; CHEST TIGHTNESS; COHORT ANALYSIS; CONTROLLED STUDY; CROHN DISEASE; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG INFUSION; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; ENTERITIS; FOLLOW UP; HEART PALPITATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFUSION RATE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; NAUSEA; PREMEDICATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSORIASIS; RHEUMATOID ARTHRITIS; SORE THROAT; SWELLING; ULCERATIVE COLITIS;

ANTIBODIES, MONOCLONAL; COHORT STUDIES; GASTROINTESTINAL AGENTS; HUMANS; INFLAMMATORY BOWEL DISEASES; INFUSIONS, INTRAVENOUS; PROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 80955177484     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2011.04699.x     Document Type: Article

References (23)

1. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462-76. (Pubitemid 41770166)
2. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-9. (Pubitemid 34621118)
3. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340: 1398-405. (Pubitemid 29205403)
4. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004; 350: 876-85. (Pubitemid 38252535)
5. Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999; 354: 1932-9.
6. St Clair EW, van der Heijde DM, Smolen JS, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004; 50: 3432-43. (Pubitemid 39488667)
7. Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005; 366: 1367-74. (Pubitemid 41443403)
8. Ricart E, Sandborn WJ,. Infliximab for the treatment of fistulas in patients with Crohn's disease. Gastroenterology 1999; 117: 1247-8.
9. Cheifetz A, Smedley M, Martin S, et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol 2003; 98: 1315-24. (Pubitemid 36741529)
10. Ducharme J, Pelletier C, Zacharias R,. The safety of infliximab infusions in the community setting. Can J Gastroenterol 2010; 24: 307-11.
11. Fidder H, Schnitzler F, Ferrante M, et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut 2009; 58: 501-8.
12. Vermeire S, Noman M, Van Assche G, et al. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut 2007; 56: 1226-31. (Pubitemid 47300423)
13. Van Assche G, Magdelaine-Beuzelin C, D'Haens G, et al. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 2008; 134: 1861-8. (Pubitemid 351790744)
14. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010; 362: 1383-95.
15. Ochenrider MG, Patterson DJ, Aboulafia DM,. Hepatosplenic T-cell lymphoma in a young man with Crohn's disease: case report and literature review. Clin Lymphoma Myeloma Leuk 2010; 10: 144-8.
16. Befrits R, Malmstrom L, Forsell A, Bark LA, Blomquist L,. One hour infiximab infusion can replace two hour infusion in maintenance treatment of Crohns disease without shortcomings, in patients treated for up to three years. Gastroenterology 2008; 134: A402-A402.
17. Bhat S, Sharma D, Doherty P, Tham TC, Caddy GR,. Are accelerated infliximab infusions safe in patients with inflammatory bowel disease? Inflamm Bowel Dis 2010; 16: 1922-5.
18. Clare DF, Alexander FC, Mike S, et al. Accelerated infliximab infusions are safe and well tolerated in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2009; 21: 71-5.
19. Van Assche G, Vermeire S, Noman M, et al. Infliximab administered with shortened infusion times in a specialized IBD infusion unit: a prospective cohort study. J Crohns Colitis 2010; 4: 329-33.
20. Rojany M, Trudeau W, Prindiville T,. Safety of a rapid one-hour infusion of infliximab in Crohn's disease patients. Am J Gastroenterol 2005; 100: S305-6.
21. Buch MH, Bryer D, Lindsay S, Rees-Evans B, Fairclough A, Emery P,. Shortening infusion times for infliximab administration. Rheumatology 2006; 45: 485-6.
22. Yeckes AR, Hoffenberg EJ, Yeckes AR, Hoffenberg EJ,. Rapid infliximab infusions in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2009; 49: 151-4.
23. Farrell RJ, Alsahli M, Jeen YT, Falchuk KR, Peppercorn MA, Michetti P,. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology 2003; 124: 917-24. (Pubitemid 36389794)